Status: Recruiting
The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy
The aim of this study is to evaluate the clinical efficacy of everolimus as an adjunctive therapy for refractory epilepsy. The significance lies in addressing whether the mTOR inhibitor sirolimus has antiepileptic adjunctive effects for a broader range of patients with refractory epilepsy, with the hope of providing a new mTOR-targeted antiepileptic adjunctive medication regimen that is administered only during epileptic events and can be widely used for various types of refractory epilepsy.
Participants needed: 5
Trial details
Phase: Early Phase 1Age: 18-60Biological sex: AllType: InterventionalSponsor: Xuanwu Hospital, BeijingUpdated: Apr 7, 2026Locations: 1
Eligibility criteria
Age between 18 and 60 years (inclusive), regardless of sex. [+8]
Diagnosis of primary generalized epilepsy. [+18]